US2019292242A1PendingUtilityA1
Hydrolyzed Jellyfish Collagen Types I, II, and V and Use Thereof
Est. expiryFeb 22, 2037(~10.6 yrs left)· nominal 20-yr term from priority
Inventors:Ahmad Alkayali
A61P 39/00A61P 39/06A61P 9/14A61P 25/28A61P 29/00A61P 17/00A61P 19/02A61P 25/00A61K 8/65A61Q 19/00A23L 2/00A61Q 19/08A61K 38/014C07K 14/78A61K 38/00A61K 35/614C12P 21/06A61K 8/00
32
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Hydrolyzed collagen types I, II, and V powder compositions, method of preparing the compositions, and use of the compositions in treating a variety of ailments. The compositions are topically or orally administered to an individual at a daily dosage between 1500 mg and 2000 mg.
Claims
exact text as granted — not AI-modifiedI claim:
1 . A method of providing collagen type I, collagen type II, and collagen type V as a supplement comprising:
a. administering to an individual an effective daily dose of a jellyfish derived material, and wherein the jellyfish derived material comprises hydrolyzed collagen type I, hydrolyzed collagen type II, and hydrolyzed collagen type V.
2 . The method of claim 1 wherein the jellyfish-derived material derived from a group of jellyfish species comprising Stomolophus meleagris and Acromitus hardenbergi.
3 . The method of claim 1 wherein each of the hydrolyzed collagen type I, hydrolyzed collagen type II, and hydrolyzed collagen type V have an average molecular weight between 4 kilodaltons and 20 kilodaltons.
4 . The method of claim 3 wherein each of the hydrolyzed collagen type I, hydrolyzed collagen type II, and Hydrolyzed collagen type V have an average molecular weight between 15 kilodaltons and 20 kilodaltons.
5 . The method of claim 1 , wherein the supplement is administered and formulated as a topical cream.
6 . The method of claim 5 , wherein the topical cream prevents an ailment comprising; neurodegenerative disease, degenerative joint diseases, joint defects, osteoarthritis, vascular disease, fatigue, cell oxidation, photo-aging, skin conditions, calcium binding proteins, memory loss, and decreased brain function.
7 . The method of claim 5 , wherein an effective daily amount is between 200 mg and 5000 mg.
8 . The method of claim 5 , wherein the effective daily amount is between 1500 mg and 2000 mg.
9 . The method of claim 1 wherein the supplement is orally administered.
10 . The method of claim 9 , wherein the orally administered supplement is a formulation comprising; one or more gelatin capsules, one or more aqueous suspensions, one or more oil suspensions, one or more elixirs, one or more tablets, and a powder.
11 . The method of claim 10 , wherein the orally administered supplement prevents an ailment comprising; neurodegenerative disease, degenerative joint diseases, joint defects, osteoarthritis, vascular disease, fatigue, cell oxidation, photo-aging, skin conditions, calcium binding proteins, memory loss, and decreased brain function.
12 . The method of claim 10 , wherein the effective daily does is between 200 mg and 5000 mg.
13 . The method of claim 10 , wherein the effective daily does is between 1500 mg and 2000 mg.Join the waitlist — get patent alerts
Track US2019292242A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.